Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.57 |
| ▸ | FLT1 | P17948 | 4/20 | 0.57 |
| ▸ | FLT4 | P35916 | 4/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141369 | 0.82 | KDR (0.57) | KDRFLT1FLT4ROCK1MKNK1 | |
| SCHEMBL140688 | 0.82 | KDR (0.57) | KDRFLT1FLT4MKNK1CDK2 | |
| SCHEMBL141294 | 0.82 | KDR (0.57) | KDRFLT1FLT4AURKAROCK1 | |
| SCHEMBL16200044 | 0.79 | ROCK1 (0.51) | KDRROCK1CDK2 | |
| SCHEMBL148200 | 0.79 | KDR (0.61) | KDRFLT1FLT4AURKAROCK1 | |
| SCHEMBL14193374 | 0.78 | MAPK8 (0.62) | MKNK1 | |
| SCHEMBL19089378 | 0.78 | RPS6KA5 (0.59) | KDRROCK1CDK2 | |
| SCHEMBL142677 | 0.77 | ROCK1 (0.62) | KDRFLT1FLT4ROCK1 | |
| SCHEMBL5096812 | 0.77 | ROCK1 (0.49) | ROCK1CDK2 | |
| SCHEMBL3814633 | 0.77 | MAPK8 (0.71) | MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KIM YUNTAE (US) | 2004-09-02 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KIM YUNTAE (US) | 2004-09-02 | — | — | US | disclosed |
| WO-2002102783-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885FLT1 565/4885FLT4 727/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885FLT1 565/4885FLT4 727/4885 |
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885FLT4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.